The settlement followed government intervention in a qui tam suit alleging Alphama paid kickbacks in the form of sham consulting arrangements, payments for attendance at meetings and so-called educational grants in order to increase sales of Kadian, a morphine-based drug, according to the release.
Read the release on the Alpharma settlement.